Abbott Laboratories (ABT) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pfizer (PFE) has outperformed Abbott Laboratories (ABT) over the past year, gaining 9.4% versus a loss of 19.6%. Over five years, ABT leads with a -18.2% price change compared with -49.3% for PFE. Abbott Laboratories is the larger company by market cap ($178.39 billion vs $156.18 billion), about 1.1 times the size.
On valuation, Pfizer trades at a lower forward P/E (9.3x vs 17.3x for Abbott Laboratories). Pfizer offers the higher dividend yield (7.85% vs 2.45%). Abbott Laboratories converts more of its revenue into profit, with a net margin of 14.7% versus 12.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABT | PFE |
|---|---|---|
| Share price | $103.00 | $27.40 |
| Market cap | $178.39B | $156.18B |
| 1-day change | -0.84% | -0.51% |
| YTD return | -17.79% | +10.04% |
| 1-year return | -19.60% | +9.42% |
| 5-year return | -18.18% | -49.26% |
| P/E ratio (TTM) | 38.43 | 39.14 |
| Forward P/E | 17.35 | 9.28 |
| EPS (TTM) | $2.68 | $0.70 |
| Dividend yield | 2.45% | 7.85% |
| Annual dividend | $2.52 | $2.15 |
| Revenue (latest FY) | $44.33B | $62.58B |
| Revenue growth (YoY) | +5.67% | -1.65% |
| Net income (latest FY) | $6.52B | $7.77B |
| Gross margin | 56.42% | 74.33% |
| Operating margin | 18.17% | — |
| Net margin | 14.72% | 12.42% |
| 52-week high | $129.85 | $31.44 |
| 52-week low | $81.97 | $23.62 |
| Distance from 52-week high | -20.68% | -12.85% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.45% | +10.29% |
| Average volume | 8.89M | 33.52M |
| Shares outstanding | 1.73B | 5.70B |
| Employees | 122,000 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PFE has outperformed ABT by 29.0 percentage points over the past year.
- Pfizer offers a meaningfully higher dividend yield (7.85% vs 2.45%).
- Abbott Laboratories grew revenue faster in its latest fiscal year (+5.67% vs -1.65%).
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
ABT vs PFE FAQ
Which is bigger, Abbott Laboratories or Pfizer?
Abbott Laboratories (ABT) is larger, with a market capitalization of $178.39B compared with $156.18B for Pfizer (PFE).
Which stock has performed better over the past year, ABT or PFE?
PFE returned +9.42% over the past 12 months, compared with -19.60% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABT or PFE?
ABT has the lower trailing P/E at 38.4, versus 39.1 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Abbott Laboratories or Pfizer?
Pfizer has the higher yield at 7.85%, compared with 2.45% for Abbott Laboratories.
Are Abbott Laboratories and Pfizer in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.